These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34079334)

  • 1. CD24 Contributes to Treatment Effect in ABC-DLBCL Patients with R-CHOP Resistance.
    Qiao LY; Li HB; Zhang Y; Shen D; Liu P; Che YQ
    Pharmgenomics Pers Med; 2021; 14():591-599. PubMed ID: 34079334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCND2 mRNA Expression Is Correlated With R-CHOP Treatment Efficacy and Prognosis in Patients With ABC-DLBCL.
    Wang D; Zhang Y; Che YQ
    Front Oncol; 2020; 10():1180. PubMed ID: 32850340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long noncoding RNA XIST: a novel independent prognostic biomarker for patients with ABC-DLBCL receiving R-CHOP treatment.
    Li HB; Wang D; Zhang Y; Shen D; Che YQ
    Carcinogenesis; 2024 Jul; 45(7):500-509. PubMed ID: 38426786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IGFBP3 Enhances Treatment Outcome and Predicts Favorable Prognosis in ABC-DLBCL.
    Li HB; Wang D; Zhang Y; Shen D; Che YQ
    J Oncol; 2023; 2023():1388041. PubMed ID: 36660244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.
    Wong KK; Gascoyne DM; Soilleux EJ; Lyne L; Spearman H; Roncador G; Pedersen LM; Møller MB; Green TM; Banham AH
    Oncotarget; 2016 Aug; 7(33):52940-52956. PubMed ID: 27224915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3K/AKT inhibition reverses R-CHOP resistance by destabilizing SOX2 in diffuse large B cell lymphoma.
    Chen J; Ge X; Zhang W; Ding P; Du Y; Wang Q; Li L; Fang L; Sun Y; Zhang P; Zhou Y; Zhang L; Lv X; Li L; Zhang X; Zhang Q; Xue K; Gu H; Lei Q; Wong J; Hu W
    Theranostics; 2020; 10(7):3151-3163. PubMed ID: 32194860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.
    Iqbal J; Meyer PN; Smith LM; Johnson NA; Vose JM; Greiner TC; Connors JM; Staudt LM; Rimsza L; Jaffe E; Rosenwald A; Ott G; Delabie J; Campo E; Braziel RM; Cook JR; Tubbs RR; Gascoyne RD; Armitage JO; Weisenburger DD; Chan WC
    Clin Cancer Res; 2011 Dec; 17(24):7785-95. PubMed ID: 21933893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma.
    Nowakowski GS; Chiappella A; Gascoyne RD; Scott DW; Zhang Q; Jurczak W; Özcan M; Hong X; Zhu J; Jin J; Belada D; Bergua JM; Piazza F; Mócikova H; Molinari AL; Yoon DH; Cavallo F; Tani M; Yamamoto K; Izutsu K; Kato K; Czuczman M; Hersey S; Kilcoyne A; Russo J; Hudak K; Zhang J; Wade S; Witzig TE; Vitolo U
    J Clin Oncol; 2021 Apr; 39(12):1317-1328. PubMed ID: 33621109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
    Xu-Monette ZY; Li L; Byrd JC; Jabbar KJ; Manyam GC; Maria de Winde C; van den Brand M; Tzankov A; Visco C; Wang J; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Wang M; Hagemeister FB; Piris MA; Han van Krieken J; Medeiros LJ; Li Y; van Spriel AB; Young KH
    Blood; 2016 Dec; 128(26):3083-3100. PubMed ID: 27760757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.
    Hu S; Xu-Monette ZY; Tzankov A; Green T; Wu L; Balasubramanyam A; Liu WM; Visco C; Li Y; Miranda RN; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Zhao X; van Krieken JH; Huang Q; Huh J; Ai W; Ponzoni M; Ferreri AJ; Zhou F; Slack GW; Gascoyne RD; Tu M; Variakojis D; Chen W; Go RS; Piris MA; Møller MB; Medeiros LJ; Young KH
    Blood; 2013 May; 121(20):4021-31; quiz 4250. PubMed ID: 23449635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
    J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD24 is a surrogate for 'immune-cold' phenotype in aggressive large B-cell lymphoma.
    Higashi M; Momose S; Takayanagi N; Tanaka Y; Anan T; Yamashita T; Kikuchi J; Tokuhira M; Kizaki M; Tamaru JI
    J Pathol Clin Res; 2022 Jul; 8(4):340-354. PubMed ID: 35289116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implication of immune cell signature of tumor microenvironment in diffuse large B-cell lymphoma.
    Yu H; Fu D; Xu PP; Cheng S; Wang L; Zhang YZ; Zhao WL
    Hematol Oncol; 2021 Dec; 39(5):616-624. PubMed ID: 34331367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center.
    Huang H; Fan L; Fu D; Lin Q; Shen J
    Ann Palliat Med; 2020 Jul; 9(4):1442-1452. PubMed ID: 32648457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response and survival benefit with chemoimmunotherapy in Epstein-Barr virus-positive diffuse large B-cell lymphoma.
    Beltran BE; Quiñones P; Morales D; Malaga JM; Chavez JC; Sotomayor EM; Castillo JJ
    Hematol Oncol; 2018 Feb; 36(1):93-97. PubMed ID: 28639256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Relationship of C1QA level and therapeutic effect and prognosis of DLBCL patients treated with R-CHOP].
    Wang YR; Yang JL; Qin Y; Zhou SY; Liu P; He XH; Jiang SY; Zhao FY; Zhong QF; Zhou Y; Li Y; Xu M; Yu XB; Han XH; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2021 Dec; 43(12):1310-1315. PubMed ID: 34915642
    [No Abstract]   [Full Text] [Related]  

  • 17. Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients.
    Wong KK; Gascoyne DM; Brown PJ; Soilleux EJ; Snell C; Chen H; Lyne L; Lawrie CH; Gascoyne RD; Pedersen LM; Møller MB; Pulford K; Murphy D; Green TM; Banham AH
    Leukemia; 2014 Feb; 28(2):362-72. PubMed ID: 23884370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An oxidative stress-based mechanism of doxorubicin cytotoxicity suggests new therapeutic strategies in ABC-DLBCL.
    Mai Y; Yu JJ; Bartholdy B; Xu-Monette ZY; Knapp EE; Yuan F; Chen H; Ding BB; Yao Z; Das B; Zou Y; Young KH; Parekh S; Ye BH
    Blood; 2016 Dec; 128(24):2797-2807. PubMed ID: 27737889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune microenvironment-related gene mapping predicts immunochemotherapy response and prognosis in diffuse large B-cell lymphoma.
    Chen W; Liang W; He Y; Liu C; Chen H; Lv P; Yao Y; Zhou H
    Med Oncol; 2022 Jan; 39(4):44. PubMed ID: 35092504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TRPM4 expression is associated with activated B cell subtype and poor survival in diffuse large B cell lymphoma.
    Loo SK; Ch'ng ES; Md Salleh MS; Banham AH; Pedersen LM; Møller MB; Green TM; Wong KK
    Histopathology; 2017 Jul; 71(1):98-111. PubMed ID: 28248435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.